As the global pharmaceutical community gathers for CPHI, the challenge of choosing the right CDMO (Contract Development and Manufacturing Organization) remains a deeply personal decision for drug developers. Rather than just finding a supplier, it is about finding a collaborative partner who listens, adapts, and leads your project as their own.
With this partner-first mindset, Skyepharma is pleased to announce its participation at CPHI once again. As an independent French CDMO based near Lyon, we have spent over 30 years building a reputation for scientific integrity and technical care. Operating from our state-of-the-art GMP-compliant facility, our team of 200 dedicated specialists supports pharmaceutical and biotech companies worldwide.Our site is fully certified by major international agencies, including the FDA, EMA, and ANVISA. We are specialized in solving complex formulation challenges for oral solid dosage (OSD) forms including modified-release, multi-layer tablets, and highly potent compounds (HPAPIs). Whether you are looking to safely accelerate a clinical pipeline, execute a seamless technical transfer, or scale up commercial production, the Skyepharma team is ready to sit down, understand your unique challenges, and work hand-in-hand to bring your therapy to life.
Successfully bringing a drug to market requires more than just machinery; it requires a deep alignment of scientific, regulatory, legal, and operational expertise. To ensure all your project questions can be answered in real-time, Skyepharma is bringing a comprehensive, multidisciplinary team to CPHI.
At Booth 6K74, you will have the opportunity to meet with key representatives from our:
Having our full team in one place means we can discuss every phase of your project from the laboratory bench to the patient in a single, productive meeting.
Skyepharma has a proven track record of successful OSD project implementations, from early-stage drug development to complex scale-up. We specialize in overcoming formulation hurdles for solid oral dosage forms, utilizing innovative technologies to improve bioavailability, control release profiles, and ensure patient compliance.
Our core CDMO strengths include:
Advanced Drug Development: Tailored formulation services to turn complex molecules into scalable, stable oral solid dose therapies.
Flawless Tech Transfer: A structured, risk-mitigated technology transfer process that minimizes downtime and ensures regulatory alignment across jurisdictions.
Reliable Commercial Manufacturing: High-quality GMP production facilities capable of handling complex multi-layer tablets, hard capsules, and high-containment molecules.
As the global drug pipeline shifts toward increasingly complex and targeted therapeutics, the demand for highly potent drug manufacturing continues to grow. To meet these challenges, Skyepharma features two fully segregated and contained HPAPI capacities.
Equipped with state-of-the-art containment technologies and strict pressure-cascade systems, these dedicated facilities are designed to safely handle highly potent molecules up to OEB 5 (Occupational Exposure Band 5). Whether your project involves low-dose highly active compounds or oncology treatments, our specialized team guarantees maximum operator safety and absolute cross-contamination prevention, providing a secure, compliant pathway from formulation to commercial scale.
In addition to technical discussions, we believe that the best pharmaceutical partnerships are built on strong relationships.
To celebrate our French heritage and foster great conversations, the Skyepharma team invites you to our traditional Wine & Cheese networking event, starting at 16:30 PM daily. It is the perfect opportunity to unwind after a busy day on the CPHI exhibition floor, meet our team in a relaxed setting, and network with other industry professionals.